These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11009708)

  • 21. Little biotech on the prairie.
    Wolfson W
    Chem Biol; 2007 Sep; 14(9):969-71. PubMed ID: 17884626
    [No Abstract]   [Full Text] [Related]  

  • 22. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. 25 breakout companies--biotech: Crucell.
    Stipp D
    Fortune; 2005 May; 151(10):155, 158. PubMed ID: 15931764
    [No Abstract]   [Full Text] [Related]  

  • 24. Does biotech M&A benefit investors?
    Jacobs T
    Nat Biotechnol; 2004 Sep; 22(9):1085. PubMed ID: 15340472
    [No Abstract]   [Full Text] [Related]  

  • 25. Biotech business Down Under.
    Beckley C
    Nature; 2004 Jun; 429(6991 Suppl):5-9. PubMed ID: 15175704
    [No Abstract]   [Full Text] [Related]  

  • 26. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 27. How changes in drug-safety regulations affect the way drug and biotech companies invest in innovation.
    Reed SD; Califf RM; Schulman KA
    Health Aff (Millwood); 2006; 25(5):1309-17. PubMed ID: 16966727
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Elan a turnaround?
    Jacobs T
    Nat Biotechnol; 2003 Sep; 21(9):985. PubMed ID: 12949557
    [No Abstract]   [Full Text] [Related]  

  • 29. Nasdaq dilutes its biotech index.
    Dorey E
    Nat Biotechnol; 2004 Jan; 22(1):9. PubMed ID: 14704690
    [No Abstract]   [Full Text] [Related]  

  • 30. Is there balm in Gilead?
    Jacobs T
    Nat Biotechnol; 2006 Dec; 24(12):1478. PubMed ID: 17160040
    [No Abstract]   [Full Text] [Related]  

  • 31. How Genentech got it.
    Stipp D
    Fortune; 2003 Jun; 147(11):81-2, 84, 86 passim. PubMed ID: 12800575
    [No Abstract]   [Full Text] [Related]  

  • 32. Biotechnology in Ireland: hard work, money and the brain gain.
    O'Neill MF
    Drug Discov Today; 2007 Feb; 12(3-4):108-11. PubMed ID: 17275730
    [No Abstract]   [Full Text] [Related]  

  • 33. Where have all the investors gone?: the case for consolidation.
    Esposito RS; Ostro MJ
    Nat Biotechnol; 1998 May; 16 Suppl():63. PubMed ID: 9591277
    [No Abstract]   [Full Text] [Related]  

  • 34. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 35. Sunbaked biotechnology in Australia.
    Littlejohn T
    Nat Biotechnol; 2002 Sep; 20(9):873-7. PubMed ID: 12205502
    [No Abstract]   [Full Text] [Related]  

  • 36. Can personalized drugs pay off?
    Stipp D
    Fortune; 2002 May; 145(10):168. PubMed ID: 12025349
    [No Abstract]   [Full Text] [Related]  

  • 37. Overcoming the challenges in the pharma/biotech industry.
    Graul AI; Prous JR
    Drug News Perspect; 2007; 20(1):57-68. PubMed ID: 17332900
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biotechs hold their own in shifting industry.
    Mitchell P
    Nat Biotechnol; 2002 Nov; 20(11):1065-6. PubMed ID: 12410238
    [No Abstract]   [Full Text] [Related]  

  • 39. Biotechs hedge against big pharma givebacks.
    Dorey E
    Nat Biotechnol; 1999 May; 17(5):416-7. PubMed ID: 10331784
    [No Abstract]   [Full Text] [Related]  

  • 40. UK biotech smashes financing record.
    Nat Biotechnol; 2015 Sep; 33(9):889. PubMed ID: 26348941
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.